Tebipenem

2,2- Dimethylpropanoyloxymethyl (4R, 5S, 6S ) -3 - [1 - (4,5- dihydro- 1, 3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-2-carboxylat (IUPAC)

J01DH

Antibiotic

Template: Infobox chemical / molecular formula search available

Tebipenempivoxil is a drug that belongs to the group of carbapenems and is orally effective. In Japan, it received approval for the treatment of certain infectious diseases in children in February 2009. Tebipenempivoxil is sold there by the company Meiji Seika under the name Orapenem. In Europe, there is no admission.

Pharmacology

Tebipenempivoxil is a prodrug of Tebipenems, a drug selected from the group of β -lactam antibiotics, bactericidal by inhibiting bacterial cell wall synthesis.

Spectrum

Tebipenempivoxil is approved in Japan for the treatment of children, as these oral antibiotics often better tolerated than infusions. Below is treatment with Tebipenem at by pathogens such as pneumococci and Haemophilus influenza - which often develop resistance to other antibiotics - causing infectious diseases such as otitis media, pneumonia, and sinusitis.